)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cardiff Oncology
Cardiff Oncology (CRDF) investor relations material
Cardiff Oncology Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Q3 net loss narrowed year over year as R&D spending declined; $33.8M in cash, cash equivalents and short-term investments is projected to fund operations through Q3 2027.
The Phase 2 mCRC trial remains ongoing, with a registrational global Phase 3 trial of ~640 patients in preparation and potential initiation in Q1 2027.
Financial highlights
Q3 2026 royalty revenue was $171K vs. $120K; operating expenses were $9.4M vs. $12.1M, and net loss was $8.9M vs. $11.3M.
9M 2026 royalty revenue was $316K vs. $350K; operating expenses were $32.0M vs. $41.5M, and net loss was $30.4M vs. $38.6M.
Q3 R&D expense fell to $5.0M from $8.2M; SG&A rose to $4.4M from $3.9M, primarily due to NMS-related legal and professional fees.
9M R&D expense fell to $17.7M from $30.3M; SG&A rose to $14.3M from $11.2M, including legal fees and severance costs.
Interest income was $0.4M vs. $0.7M in Q3 and $1.3M vs. $2.5M for 9M.
Outlook and guidance
Current projections indicate capital resources fund operations through Q3 2027, but not for at least 12 months following issuance of the financial statements.
Planned CRDF-005 is a global randomized Phase 3 trial of onvansertib 30 mg plus FOLFIRI/bev vs. FOLFIRI/bev standard of care, targeting ~640 patients; potential start is Q1 2027.
EMA scientific advice is being sought on Phase 3 plans; clinical material manufacturing and companion diagnostic regulatory activities remain on track.
Additional CMML trial data are scheduled for presentation at the December 2026 ASH meeting.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cardiff Oncology
- A ~640-patient Phase III trial is planned for 1Q 2027, pending funding.CRDF
H.C. Wainwright 28th Annual Global Investment Conference - Vote to increase authorized shares aims to support future growth and financing flexibility.CRDFProxy filing
- Shareholders will vote on a major increase in authorized shares at the October 2026 meeting.CRDFProxy filing
- Vote sought to increase authorized shares and permit meeting adjournment if needed.CRDFProxy filing
- Phase 2 success for onvansertib in mCRC; cash runway into Q3 2027, but litigation risk remains.CRDFQ2 2026
- Onvansertib shows strong efficacy and safety in first-line RAS-mutated MCRC, with major updates due in Q1 2026.CRDFNoble Capital Markets Emerging Growth Virtual Investor Conference
- Advancing a well-tolerated PLK1 inhibitor to global phase III for RAS-mutated colorectal cancer.CRDFJefferies Global Healthcare Conference 2026
- 30 mg onvansertib plus FOLFIRI-BEV delivers 72.2% ORR and durable benefit in RAS-mutated mCRC.CRDFStatus update
- Positive Phase 2 data, FDA alignment, and narrowed net loss offset by ongoing going concern risk.CRDFQ1 2026
Next Cardiff Oncology earnings date
UBS Global Biopharma Conference 202616 Nov, 2026
Cardiff Oncology
Next Cardiff Oncology earnings date
UBS Global Biopharma Conference 202616 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cardiff Oncology Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for various cancers. The company's primary approach involves leveraging PLK1 (Polo-like Kinase 1) inhibition to create novel cancer treatments. Their flagship product, onvansertib, is an oral selective PLK1 inhibitor currently being evaluated in combination with standard-of-care therapeutics across several clinical programs. These include treatments for KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.